Every week, physicians are handed a printout by a well-read, proactive patient. It usually contains a “biological age” score, derived from a direct-to-consumer epigenetic test or standard blood lab. The patient, chronologically 52, is thrilled to announce their biological age is 46. Or, conversely, they are anxious because their score came back at 58.
Then comes the inevitable question: “What should we do about this?” For the physician, this is where the conversation stalls. A single, aggregate biological age score is scientifically interesting, but not entirely clinically useful and potentially misleading. If a patient is biologically older than their chronological age, what is driving it? Is it their cardiovascular system? Their liver? Their immune system?
You cannot prescribe a targeted intervention for a generalized “aging” score. Without clinical actionability, these single-score metrics remain firmly in the realm of wellness tracking rather than predictive health.
To bridge the gap between longevity science and true clinical utility, we have to move beyond the aggregate score. We must recognize a fundamental truth of human biology: Our bodies do not age uniformly.
Real physician voices, twice a week
Free, and one click to unsubscribe.
The myth of uniform aging
We have long known that aging is the primary risk factor for almost every chronic disease, from neurodegeneration to cardiovascular failure. But a 52-year-old individual does not have a uniformly 52-year-old body.
A patient might possess the cardiovascular health of a 40-year-old, yet carry the aging liver of a 54-year-old due to early metabolic dysfunction. When a biological age test blends these diverse systems into one average number, the most critical data is lost. The healthy heart masks the struggling liver, hiding the exact localized risk the physician needs to see.
If we want to intervene before chronic disease manifests, we need higher resolution. We need to look at aging at the organ level.
Proteomics: the real-time window into organ health
The key to unlocking organ-specific aging lies in plasma proteomics. If genomics provides the static blueprint of what might happen to a patient, proteomics reveals exactly what is happening in real time.
Proteins are the active cellular machinery of the body. As cells undergo stress, damage, or senescence, they shed specific proteins into the bloodstream. Because of recent breakthroughs in proteomics and machine learning (many pioneered out of leading academic institutions like Stanford University), we can now trace thousands of these circulating proteins back to the specific organs that produced them. By analyzing these organ-specific protein signatures, we can determine the distinct health and aging of the heart, brain, kidneys, liver, and immune system from a single blood draw.
From passive tracking to clinical actionability
This shift from an aggregate score to proteomic organ profiling transforms longevity science into a practical tool for the clinic. Consider the kidneys. Traditionally, a physician monitors renal function using markers like eGFR or creatinine. However, these markers often remain in the “normal” range until significant, functional decline has already occurred.
With proteomic organ aging, a clinician can identify a patient whose kidney is aging at an accelerated rate years before traditional metabolic panels flash red. This gives the clinician the foresight and conviction needed to intervene early (perhaps by adjusting blood pressure medications, modifying diet, or closely monitoring metabolic markers), long before chronic kidney disease takes hold. The same applies to an accelerated brain, prompting earlier neurocognitive assessments, or an accelerated immune age, signaling the need to address hidden systemic inflammation.
The next era of preventive care
Health care is at a critical inflection point. Patients are highly motivated to extend their healthspan, but they are relying on current consumer tools that lack the specificity required for medical decision-making.
Physicians do not need more generalized data; they need precise, localized intelligence. By shifting our focus to proteomic, organ-specific aging, we can finally equip clinicians with the clarity they need. It moves the conversation from “How old are you?” to “Where are you aging fastest, and how can we protect that system today?”
That is how we move from managing chronic disease to predicting and preventing it.
Paul Coletta is cofounder and CEO of Vero Bioscience, a predictive health company on a mission to end age-related chronic disease. Vero uses proteomics and machine learning to measure the biological age of individual organs, revealing where the body is aging fastest to help people take personalized action before disease develops.
Prior to Vero, Paul spent more than 25 years building consumer businesses, iconic brands, and high-performing teams across technology, media, consumer products, nutrition, and health. He has held executive leadership roles at The Walt Disney Company, MTV Networks, Nickelodeon, Hewlett-Packard, Jamba Juice, and Urban Remedy, where he served as CEO for more than a decade. Throughout his career, he has focused on building companies that translate emerging ideas into products and experiences that meaningfully improve people’s lives, with a longstanding commitment to advancing health through nutrition and preventive lifestyle.


